An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice.

Weisheng LuHong TianPeng QianYing LiYongkang WangYang GeWenbo SaiXiang-Dong GaoWenbing Yao

Published in: British journal of pharmacology (2020)

OHP2 is a potential, orally bioavailable, candidate drug for the treatment of Type 2 diabetes. Its transcytosis mechanism of uptake could help in the development of absorption enhancers of OHP2.

Keyphrases

body weight
blood brain barrier
high fat diet induced
emergency department
type diabetes
risk assessment
drug induced
combination therapy
replacement therapy
climate change